EMA Recommends EU-Wide Desloratadine Switch
Teva subsidiary Ratiopharm has secured EMA's backing for the EU-wide switch of allergy drug desloratadine, representing the second reclassification approved by the regulator this year.
Teva subsidiary Ratiopharm has secured EMA's backing for the EU-wide switch of allergy drug desloratadine, representing the second reclassification approved by the regulator this year.